JP2006510382A - 遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け - Google Patents
遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け Download PDFInfo
- Publication number
- JP2006510382A JP2006510382A JP2004562300A JP2004562300A JP2006510382A JP 2006510382 A JP2006510382 A JP 2006510382A JP 2004562300 A JP2004562300 A JP 2004562300A JP 2004562300 A JP2004562300 A JP 2004562300A JP 2006510382 A JP2006510382 A JP 2006510382A
- Authority
- JP
- Japan
- Prior art keywords
- infection
- profile data
- data set
- subject
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 573
- 230000014509 gene expression Effects 0.000 title claims description 241
- 230000004968 inflammatory condition Effects 0.000 title claims description 21
- 238000000034 method Methods 0.000 claims abstract description 346
- 238000005259 measurement Methods 0.000 claims abstract description 112
- 230000003321 amplification Effects 0.000 claims abstract description 78
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 78
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 57
- 208000024891 symptom Diseases 0.000 claims description 138
- 210000004369 blood Anatomy 0.000 claims description 103
- 239000008280 blood Substances 0.000 claims description 103
- 238000011282 treatment Methods 0.000 claims description 80
- 210000004027 cell Anatomy 0.000 claims description 68
- 230000002757 inflammatory effect Effects 0.000 claims description 59
- 239000003814 drug Substances 0.000 claims description 55
- 244000052769 pathogen Species 0.000 claims description 55
- 229940079593 drug Drugs 0.000 claims description 50
- 210000001124 body fluid Anatomy 0.000 claims description 40
- 230000009885 systemic effect Effects 0.000 claims description 40
- 239000010839 body fluid Substances 0.000 claims description 39
- 201000010099 disease Diseases 0.000 claims description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 39
- 230000001717 pathogenic effect Effects 0.000 claims description 39
- 230000001225 therapeutic effect Effects 0.000 claims description 35
- 230000000875 corresponding effect Effects 0.000 claims description 31
- 230000002458 infectious effect Effects 0.000 claims description 31
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 30
- 238000003556 assay Methods 0.000 claims description 30
- 230000036961 partial effect Effects 0.000 claims description 30
- 208000014674 injury Diseases 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 230000008733 trauma Effects 0.000 claims description 28
- 208000031729 Bacteremia Diseases 0.000 claims description 24
- 230000037081 physical activity Effects 0.000 claims description 22
- 235000016709 nutrition Nutrition 0.000 claims description 21
- 238000004820 blood count Methods 0.000 claims description 19
- 230000036772 blood pressure Effects 0.000 claims description 19
- 230000036760 body temperature Effects 0.000 claims description 19
- 210000000265 leukocyte Anatomy 0.000 claims description 19
- 230000000813 microbial effect Effects 0.000 claims description 18
- 206010035664 Pneumonia Diseases 0.000 claims description 17
- 206010014665 endocarditis Diseases 0.000 claims description 17
- 230000000149 penetrating effect Effects 0.000 claims description 17
- 238000001356 surgical procedure Methods 0.000 claims description 17
- 208000019206 urinary tract infection Diseases 0.000 claims description 17
- 244000005700 microbiome Species 0.000 claims description 16
- 208000035143 Bacterial infection Diseases 0.000 claims description 15
- 206010017533 Fungal infection Diseases 0.000 claims description 15
- 208000031888 Mycoses Diseases 0.000 claims description 15
- 208000030852 Parasitic disease Diseases 0.000 claims description 15
- 208000036142 Viral infection Diseases 0.000 claims description 15
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 15
- 230000009385 viral infection Effects 0.000 claims description 15
- 230000007423 decrease Effects 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 238000012512 characterization method Methods 0.000 claims description 13
- 230000003247 decreasing effect Effects 0.000 claims description 13
- 206010040047 Sepsis Diseases 0.000 claims description 12
- 238000003860 storage Methods 0.000 claims description 12
- 238000003384 imaging method Methods 0.000 claims description 11
- 230000002503 metabolic effect Effects 0.000 claims description 11
- 230000036281 parasite infection Effects 0.000 claims description 11
- 238000002562 urinalysis Methods 0.000 claims description 11
- 206010058874 Viraemia Diseases 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 238000013507 mapping Methods 0.000 claims description 8
- 244000045947 parasite Species 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 238000002483 medication Methods 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 6
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 244000052613 viral pathogen Species 0.000 claims description 6
- 230000002596 correlated effect Effects 0.000 claims description 5
- 238000011156 evaluation Methods 0.000 claims description 5
- 238000011002 quantification Methods 0.000 claims description 5
- 238000007619 statistical method Methods 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 3
- 244000052616 bacterial pathogen Species 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 241000223960 Plasmodium falciparum Species 0.000 claims description 2
- 241000223104 Trypanosoma Species 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 244000000058 gram-negative pathogen Species 0.000 claims description 2
- 238000007620 mathematical function Methods 0.000 claims description 2
- 238000002203 pretreatment Methods 0.000 claims 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 2
- 241000709661 Enterovirus Species 0.000 claims 1
- 244000053095 fungal pathogen Species 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000000523 sample Substances 0.000 description 146
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 52
- 108090000623 proteins and genes Proteins 0.000 description 52
- 206010061218 Inflammation Diseases 0.000 description 48
- 230000004054 inflammatory process Effects 0.000 description 48
- 230000006870 function Effects 0.000 description 42
- 210000001519 tissue Anatomy 0.000 description 39
- 206010039073 rheumatoid arthritis Diseases 0.000 description 38
- 230000004044 response Effects 0.000 description 30
- 241000588724 Escherichia coli Species 0.000 description 27
- 230000000694 effects Effects 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 238000004422 calculation algorithm Methods 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 230000008859 change Effects 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 208000038016 acute inflammation Diseases 0.000 description 10
- 230000006022 acute inflammation Effects 0.000 description 10
- 230000003287 optical effect Effects 0.000 description 10
- 229960004618 prednisone Drugs 0.000 description 10
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 10
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 229960000485 methotrexate Drugs 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 7
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 7
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 6
- 102100039065 Interleukin-1 beta Human genes 0.000 description 6
- 229960001680 ibuprofen Drugs 0.000 description 6
- 239000012678 infectious agent Substances 0.000 description 6
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229940116176 remicade Drugs 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000004544 DNA amplification Effects 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000009897 systematic effect Effects 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000003435 Optic Neuritis Diseases 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 230000009274 differential gene expression Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- -1 physical Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000003161 ribonuclease inhibitor Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000021 stimulant Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 206010049590 Upper respiratory tract inflammation Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000001632 homeopathic effect Effects 0.000 description 2
- 229940082177 ibuprofen 800 mg Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000008288 physiological mechanism Effects 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 229920000024 polymyxin B Polymers 0.000 description 2
- 229960005266 polymyxin b Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 101150094083 24 gene Proteins 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 1
- 101001097889 Homo sapiens Platelet-activating factor acetylhydrolase Proteins 0.000 description 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 102100037518 Platelet-activating factor acetylhydrolase Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000007940 bacterial gene expression Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 235000006997 botanical dietary supplement Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000005256 gram-negative cell Anatomy 0.000 description 1
- 210000005255 gram-positive cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003520 lipogenic effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43525702P | 2002-12-19 | 2002-12-19 | |
| PCT/US2003/040551 WO2004057034A1 (en) | 2002-12-19 | 2003-12-19 | Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010111560A Division JP2010227111A (ja) | 2002-12-19 | 2010-05-13 | 遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006510382A true JP2006510382A (ja) | 2006-03-30 |
| JP2006510382A5 JP2006510382A5 (enExample) | 2010-07-01 |
Family
ID=32682206
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004562300A Pending JP2006510382A (ja) | 2002-12-19 | 2003-12-19 | 遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け |
| JP2010111560A Pending JP2010227111A (ja) | 2002-12-19 | 2010-05-13 | 遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010111560A Pending JP2010227111A (ja) | 2002-12-19 | 2010-05-13 | 遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1579008A1 (enExample) |
| JP (2) | JP2006510382A (enExample) |
| CN (1) | CN1751129B (enExample) |
| AU (1) | AU2003303238B2 (enExample) |
| BR (1) | BR0317612A (enExample) |
| CA (1) | CA2511237A1 (enExample) |
| MX (1) | MXPA05006804A (enExample) |
| WO (1) | WO2004057034A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010535017A (ja) * | 2007-08-03 | 2010-11-18 | エスアイアールエス‐ラブ ゲーエムベーハー | 局所感染と全身感染を区別するための遺伝子活性検出用ポリヌクレオチドの使用 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2505921A1 (en) | 2002-11-12 | 2004-05-27 | Becton, Dickinson And Company | Diagnosis of sepsis or sirs using biomarker profiles |
| EP2128270B1 (en) | 2003-08-08 | 2012-10-03 | Genenews Inc. | Osteoarthritis biomarkers and uses thereof |
| BRPI0609302A2 (pt) | 2005-04-15 | 2011-10-11 | Becton Dickinson Co | métodos para prever o desenvolvimento de sepse e para diagnosticar sepse em um indivìduo a ser testado, microarranjo, kit para prever o desenvolvimento de sepse em um indivìduo a ser testado, produto de programa de computador, computador, sistema de computador para determinar se um indivìduo é susceptìvel de desenvolver sepse, sinal digital embutido em uma onda portadora, e, interface gráfica de usuário para determinar se um indivìduo é susceptìvel de desenvolver sepse |
| AU2006294477A1 (en) * | 2005-09-27 | 2007-04-05 | Source Mdx | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis |
| CA2652239A1 (en) * | 2006-05-16 | 2007-11-29 | Source Mdx | Assessment of effect of an agent on a human biological condition using rodent gene expression panels |
| WO2008048986A2 (en) * | 2006-10-17 | 2008-04-24 | Children's Hospital Medical Center | Gene array technique for predicting response in inflammatory bowel diseases |
| TWI600759B (zh) | 2010-04-02 | 2017-10-01 | 可娜公司 | 藉由抑制群落刺激因子３（ｃｓｆ３）之天然反義轉錄物以治療ｃｓｆ３相關疾病 |
| GB201304626D0 (en) * | 2013-03-14 | 2013-05-01 | Univ Cardiff | Method of identifying a bacterial infection |
| BR112017019373A2 (pt) * | 2015-03-12 | 2018-06-05 | Koninklijke Philips N.V. | método implementado por computador, e, mídia legível por computador |
| US11031119B2 (en) * | 2019-11-13 | 2021-06-08 | Cube Click, Inc. | Dental images processed with deep learning for national security |
| CN118824376B (zh) * | 2024-09-18 | 2025-01-21 | 江苏省疾病预防控制中心(江苏省预防医学科学院) | 基于元学习技术的呼吸系统传染病人工智能辅助筛查系统 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001025473A1 (en) * | 1999-06-28 | 2001-04-12 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using calibrated gene expression profiles |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0960214A4 (en) * | 1996-12-06 | 2004-08-04 | Urocor Inc | Diagnosis of disease status on HAnd from mRNA profiles |
| US6964850B2 (en) * | 2001-11-09 | 2005-11-15 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
-
2003
- 2003-12-19 AU AU2003303238A patent/AU2003303238B2/en not_active Ceased
- 2003-12-19 CN CN200380109850.5A patent/CN1751129B/zh not_active Expired - Lifetime
- 2003-12-19 MX MXPA05006804A patent/MXPA05006804A/es unknown
- 2003-12-19 EP EP03808491A patent/EP1579008A1/en not_active Withdrawn
- 2003-12-19 BR BR0317612-6A patent/BR0317612A/pt not_active IP Right Cessation
- 2003-12-19 WO PCT/US2003/040551 patent/WO2004057034A1/en not_active Ceased
- 2003-12-19 CA CA002511237A patent/CA2511237A1/en not_active Abandoned
- 2003-12-19 JP JP2004562300A patent/JP2006510382A/ja active Pending
-
2010
- 2010-05-13 JP JP2010111560A patent/JP2010227111A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001025473A1 (en) * | 1999-06-28 | 2001-04-12 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using calibrated gene expression profiles |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010535017A (ja) * | 2007-08-03 | 2010-11-18 | エスアイアールエス‐ラブ ゲーエムベーハー | 局所感染と全身感染を区別するための遺伝子活性検出用ポリヌクレオチドの使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003303238B2 (en) | 2010-07-22 |
| CN1751129A (zh) | 2006-03-22 |
| JP2010227111A (ja) | 2010-10-14 |
| EP1579008A1 (en) | 2005-09-28 |
| WO2004057034A1 (en) | 2004-07-08 |
| CN1751129B (zh) | 2014-07-23 |
| AU2003303238A1 (en) | 2004-07-14 |
| MXPA05006804A (es) | 2006-03-30 |
| CA2511237A1 (en) | 2004-07-08 |
| BR0317612A (pt) | 2005-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508505A (ja) | 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定 | |
| JP2010227111A (ja) | 遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け | |
| AU784233B2 (en) | Systems and methods for characterizing a biological condition or agent using calibrated gene expression profiles | |
| WO2008027428A2 (en) | Gene expression profiling for identification, monitoring and treatment of transplant rejection | |
| WO2007038754A2 (en) | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis | |
| JP2005508505A5 (enExample) | ||
| US20110306512A1 (en) | Gene Expression Profiling for Identification, Monitoring, and Treatment of Osteoarthritis | |
| JP2006510382A5 (enExample) | ||
| AU2003303238A2 (en) | Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles | |
| WO2008091708A2 (en) | Gene expression profiling for identification, monitoring, and treatment of lupus erythematosus | |
| CN105506074B (zh) | 一种用于精神分裂症诊断的lncRNA标志物及试剂盒 | |
| Sinnott et al. | Differential gene expression in prostate tissue according to ejaculation frequency | |
| US20230071390A1 (en) | Assessment of pr cellular signaling pathway activity using mathematical modelling of target gene expression | |
| WO2007136728A2 (en) | Assessment of effect of an agent on a human biological condition using rodent gene expression panels | |
| EP1910571A2 (en) | Gene expression profiling for identification, monitoring and treatment of multiple sclerosis | |
| Xu et al. | Profiling transcriptomic changes and signaling pathways in atopic dermatitis by integrative analyses on multiple databases | |
| Zainal Abidin et al. | Let‐7e as Potential Diagnostic Biomarkers in Early Detection of Peri‐Implant Diseases: A Cross‐Sectional Study | |
| HK1169190A (en) | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061213 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061213 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20080520 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091113 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100212 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100219 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100312 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100319 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100409 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100416 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20100513 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110405 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110704 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120307 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120502 |